Skip to Content
MilliporeSigma
All Photos(3)

Documents

SAB4200778

Sigma-Aldrich

Anti-NRAS (internal) antibody produced in rabbit

affinity isolated antibody

Synonym(s):

Anti-GTPase NRas, Anti-transforming protein N-Ras

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

rabbit

Quality Level

200

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

mol wt

predicted mol wt ~21 kDa

species reactivity

human

concentration

~1.0 mg/mL

technique(s)

immunoblotting: 2.5-5 μg/mL using human MCF7 cell line extract
immunohistochemistry: 10-20 μg/mL using heat-retrieved formalin-fixed, paraffin-embedded human melanoma sections

UniProt accession no.

P01111

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... NRAS(4893)

General description

NRAS, also known as GTPase NRas, Transforming protein N-Ras, or Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, is a member of the Ras protein family, together with KRAS (Kirsten RAS), and HRAS (Harvey RAS), comprising a family of low-molecular-weight GTPases. The Ras family is named for a retrovirus that induced rat sarcomas that were later found to have activating RAS mutations. Ras family proteins serve as molecular switches in regulating pathways that are responsible for diverse cellular processes such as proliferation, differentiation, migration, and apoptosis.3 Ras proteins are highly homologous regarding their primary amino acid sequence and the differences among them concentrated in their C-terminal region. Anti-NRAS (internal) antibody produced in rabbit specifically recognizes human NRAS and does not cross-react with KRAS.

Immunogen

Synthetic peptide from the internal region of human NRAS protein, conjugated to KLH

Application

The antibody may be used in various immunochemical techniques including immunoblotting (predicted ∼21 kDa) and immunohistochemistry. Detection of the NRAS band by Immunoblotting is specifically inhibited by the immunizing protein.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide as preservative.

Other Notes

This product is for R&D use only, not for drug, household, or other uses.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class

10 - Combustible liquids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Esther Castellano et al.
Genes & cancer, 2(3), 216-231 (2011-07-23)
H-ras, N-ras, and K-ras are canonical ras gene family members frequently activated by point mutation in human cancers and coding for 4 different, highly related protein isoforms (H-Ras, N-Ras, K-Ras4A, and K-Ras4B). Their expression is nearly ubiquitous and broadly conserved
Eva Muñoz-Couselo et al.
OncoTargets and therapy, 10, 3941-3947 (2017-09-02)
Melanoma is one of the most common cutaneous cancers worldwide. Activating mutations in RAS oncogenes are found in a third of all human cancers and NRAS mutations are found in 15%-20% of melanomas. The NRAS-mutant subset of melanoma is more
Ha Linh Vu et al.
Pharmacological research, 107, 111-116 (2016-03-19)
Cutaneous melanoma is a devastating form of skin cancer and its incidence is increasing faster than any other preventable cancer in the United States. The mutant NRAS subset of melanoma is more aggressive and associated with poorer outcomes compared to
Douglas B Johnson et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(16), 4186-4192 (2014-06-05)
Successful targeting of specific oncogenic "driver" mutations with small-molecule inhibitors has represented a major advance in cancer therapeutics over the past 10 to 15 years. The most common activating oncogene in human malignancy, RAS (rat sarcoma), has proved to be
Ahmed A Samatar et al.
Nature reviews. Drug discovery, 13(12), 928-942 (2014-12-02)
The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes. Recently, the use of compounds targeting components of ERK signalling, such as RAF or MEK
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service